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ABSTRACT
Pancreatic cancer is difficult to diagnose in early stage. Malignant bile duct obstruction is a severe 
complication of pancreatic cancer, which can lead to poor outcomes including cholangitis, delayed treatment, 
reduced quality of life, and increased mortality. Perendoscopic placement of stents is a method widely used in the 
management of various malignant and benign pancreatico-biliary abnormalities. A 70-year-old woman came to 
Dr Moewardi General Hospital in Surakarta with the chief complaint of yellowish skin and eyes since one month 
before hospital admission. Patient was diagnosed with obstructive jaundice due to suspected of advanced stage 
pancreatic cancer. Subsequently, patient underwent endoscopic retrograde cholangiopancreatography (ERCP) 
which revealed an intrahepatic and extrahepatic bile ducts dilatation due to pancreatic tumor which infiltrated 
common bile duct, thus self expandable metallic stent (SEMS) placement was performed. Furthermore, patients 
received palliative therapy due to inadequate chemotherapy requirement.
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ABSTRAK
Kanker pankreas sulit didiagnosis pada tahap awal penyakit. Obstruksi duktus bilier merupakan komplikasi 
tingkat lanjut dari kanker pankreas yang dapat menyebabkan hasil yang buruk termasuk kolangitis, penundaan 
terapi, penurunan kualitas hidup dan peningkatan mortalitas. Pemasangan stent perendoscopik adalah metode 
yang banyak digunakan dalam manajemen obstruksi bilier-pankreas baik maligna maupun benigna. Seorang 
wanita berusia 70 tahun datang ke Rumah Sakit Umum Dr Moewardi di Surakarta dengan keluhan kulit dan 
mata kuning sejak satu bulan sebelumnya. Pasien didiagnosis menderita ikterus obstruktif et causa karsinoma 
pankreas stadium lanjut. Kemudian, pada pasien dilakukan endoscopic retrograde cholangiopancreatography 
(ERCP) yang menunjukkan adanya dilatasi duktus biliaris intrahepatal dan extrahepatal et causa tumor pankreas 
yang menginfiltrasi duktus koledokus. Oleh karena itu, dilakukan pemasangan self expandable metallic stent 
(SEMS). Selanjutnya, pasien mendapat terapi paliatif karena persyaratan kemoterapi yang tidak memadai.
Kata kunci: kanker pankreas, obstruksi bilier, self expandable metallic stent (SEMS)
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INTRODUCTION
Although the number of pancreatic cancer patients 
is only about 3% of all cancers in the United States, it 
is the fourth leading cause of death in both men and 
women, and it is responsible for 7% of all cancer-
related deaths.1 Pancreatic cancer is difficult to 
diagnose in early stage. At the time of diagnosis, 52% 
of all patients having distant metastatic disease, and 
26% have regional distribution. The survival rate in 5 
years and a year of pancreatic cancer is low.2,3
Malignant bile duct obstruction is a severe 
complication of pancreatic cancer which can lead to 
poor outcomes including cholangitis, delayed treatment 
(chemotherapy or surgery), reduced quality of life and 
increased mortality. For palliative purposes, biliary 
decompression may improve patients’ comfort by 
alleviating jaundice and pruritus.4
Perendoscopic placement of stents is a method 
widely used in the management of various malignant 
and benign pancreatico-biliary abnormalities.5 Stent 
strategies and selection may differ based on clinical 
scenario and disease stage.4 In this case report, we 
reported a geriatric patient who presented with typical 
obstructive jaundice caused by head of pancreas 
malignancy.
CASE ILLUSTRATION
A 70-year-old woman came to Dr Moewardi 
General Hospital in Surakarta with the chief complaint 
of yellowish skin and eyes eye complaints since 
one month before hospital admission. There was 
significant weight loss and decreased appetite with full 
stomach complaint and also nausea-vomit. She also 
mentioned abdominal pain especially in the epigastric 
and right hypochondriac region. During the episode 
of illness, there was no fever. History of vomiting 
blood or black starry stool was denied. No pale (clay) 
colored stool was found. Previously, the patient was 
admitted to a private hospital and had an abdominal 
ultrasound examination. She denied history of diabetes 
or hypertension. Physical examination found weak 
general condition and composmentis awareness. There 
was no abnormality in vital signs. From physical 
examination of the eye, pale conjunctiva and icteric 
sclera was found. Further, lung and heart were within 
normal limits with no hepatosplenomegaly. There was 
positive Murphy sign, palpable vesica fellea in the right 
hypochondriaca region (positive courvosier sign), no 
peripheral lymphadenopathy and no edema of the legs.
Laboratory results showed mild anemia (9.8 g/dL), 
normal leukocyte count (9200 uL), normal platelet 
count (455000 uL), with slightly elongated bleeding 
time (INR 1.59). There were hyperbilirubinemia with 
dominance of direct bilirubin (initial total bilirubin 
level was 40 mg/dL then 32.74 mg/dL, direct bilirubin 
21.28 mg/dL, indirect bilirubin 11.46 mg/dL), 
increased alkali phosphatase (964 u/L), increased 
gamma glutamyl transferase (490 μ/L), increased 
transaminase enzymes (AST 164 u/l, ALT 82 u/L), 
normal urea and creatinine level, mild hypokalemia 
(3.1 mmol/L). Examination of tumor markers showed 
normal limit of alpha feto protein (AFP) and significant 
increase of Cancer Antigen (CA) 19-9 >500 U/mL.
The abdominal ultrasound examination performed 
in the previous hospital described intrahepatic 
biliary obstruction caused by suspect of cholangitis, 
dilated vesica fellea with cholecystitis and sludge 
in it. A thoracic photo revealed aortosclerosis. 
Magnetic resonance imaging (MRI) and magnetic 
retrograde cholangiopancreatography (MRCP) 
showed that pancreatic head mass suspicion of 
malignancy which attached to the surrounding tissue 
and caused obstruction of intrahepatic and extrahepatic 
obstruction of biliary system; blood vessel supply was 
derived from branches of the superior and inferior 
pancreaticoduodenal artery; lymphadenopathy in 
the paraaortic and parailiac regions; hydrops vesica 
fellea accompanied with cholangitis, cholelithiasis 
and multiple choledocolithiasis. Examination of 
esophagogastroduodenoscope showed gastritis and 
duodenal bulbus ulcer (Forrest III).
Patient was diagnosis with obstructive jaundice 
due to suspected of advanced stage pancreatic cancer. 
Subsequently, patient underwent endoscopic retrograde 
cholangiopancreatography (ERCP) which revealed 
intrahepatic and extrahepatic bile ducts dilatation due 
to pancreatic tumor which infiltrated the common bile 
duct. Further, self-expandable metallic stent (SEMS) 
Boston Wallflex Unconvered 10 mm 8 cm placement 
was performed.
After undergoing therapeutic ERCP patient did 
not experience any post-ERCP side effects such as 
pancreatitis, bleeding or infection. Furthermore, 
patients received palliative therapy. One week 
evaluation of post-insertion of SEMS showed 
significant decrease of bilirubin (total bilirubin 22 mg/
dL then 10 mg/dL, direct bilirubin 7.31 mg/dL and 
indirect bilirubin 2.69 mg/dL). Finally, the patient was 
allowed to be outpatient with performance status score 
3 of Eastern Cooperative Oncology Group (ECOG).
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DISCUSSION
Pancreatic cancer is the fourth cause of death 
in the world.1,2 The average of new case is 28,000 
per year with most cases are found at a later stage. 
Whereas in developing countries, it is ranked as the 
fifth cause of death after lung cancer, stomach cancer, 
colon cancer, and breast cancer. Most cases were often 
found (approximately 80%) in the age between 60-80 
years old, while case in the age < 40 years old is rare. 
These cases are more common in men than women. 
The location of pancreatic cancer was found to be at 
most 65-75% in the head, 15-20% in the body, and 
only 5-10% in the tail.2,6 The 5-years survival rate in 
the overall stage is 5-7% while the survival rate in 1 
year is only 28%.2,3 
Stomachache is the most common complaint in 
patient with pancreatic cancer, which account for 
approximately 80%. The area of pain depends on the 
location of the lesion. Most of pain radiates to the 
back. Other symptoms include yellowish eyes and 
skin (jaundice), anorexia, weight loss, diarrhea and 
pale stool. The presence of bloody stool shows the 
presence of tumor erosion to the duodenum. History 
associated with diabetes mellitus, symptoms of chronic 
pancreatitis, obesity, smoking, long-term medication 
consumption, alcohol consumption, daily habits in 
processed food and diet, history of genetic and other 
factors are useful to retrieve. The presence of diabetes 
mellitus with symptoms of pain, anorexia, and weight 
loss are present in 70% of pancreatic cancer cases. 
Acute pancreatitis might occur as an effect of the 
pressure in the pancreatic duct.7
The patient was a 70-years-old woman with 
suspected pancreatic cancer, this way in accordance 
with the epidemiology of the disease. Upon admission, 
patient’s chief complaints were yellowish skin and eyes 
accompanied with significant weight loss. Patient also 
complained of indigestion in the form of decreased 
appetite, nausea and occasional vomiting. This was in 
accordance to the findings of MRI-MRCP investigation 
results that indicated the presence head of pancreas 
mass attached to surrounding tissue which caused 
biliary obstruction.
Clinical symptoms of pancreatic cancer are not 
specific in the early stage. Whereas, if there are any 
signs of biliary system blockage, especially if the 
location of lesion is on the pancreatic head, physical 
examination of the patient shows yellowish eyes and 
skin (jaundice) with pruritus, cachexia, and sometimes 
enlarging gallbladder (courvosier sign) in 20-25% 
of cases. The presence of ascites, hepatomegaly, 
Virchow’s nodes (Left supraclavicular adenopathy), 
Sister Mary Joseph's node (periumbilical adenopathy) 
suggest metastases, whereas stomach blockage 
indicated advanced stage and poor prognosis.2,7 Non-
complicated obstructive jaundice is largely due to 
pancreatic head lesions.8 Head of pancreas is a common 
site for carcinoma. Most of these cases arise in the head 
of the pancreas from ductular epithelium, but may 
also develop from pancreatic acinar cells, the lining 
of the low bile duct, the ampulla of vater (papilla) or 
rarely the duodenum. Five-year survival following 
resection is 40-70% for ampullary and only 10-20% 
for pancreatic carcinoma.9
The effects of carcinoma in the ampullary region 
consists of: (1) General effects of malignant disease-
weakness, weight loss; (2) Obstructed common bile 
duct; dilated gallblader and bile ducts-jaundice, 
pruritus; (3) Obstructed pancreatic duct-steatorrhoea, 
diabetes; (4) Local invasion:blood vessels (portral, 
superior mesenteric)-encasement, thrombosis; nerves-
back and epigastric pain; (5) Duodenal invasion-
occasional duodenal obstruction, positive occult blood; 
(6) Tumor metastases-regional glands, liver, lungs, 
peritoneum.9
Patients who have mass in the pancreatic capillary 
(part of the periampular region carcinoma) experience 
symptoms and signs corresponding to the extra and 
intrahepatic biliary obstruction, accompanied by vesica 
fellea dilatation (positive Courvisier sign). There was 
no invasion to celiac vessels, superior mesenteric, 
portal to the inferior cava vein. The pancreatic 
mass was supplied by the superior and inferior 
pancreaticoduodenal artery branches. However, 
patients could be categorized as having advanced stage 
disease because of the presence of metastases into 
non-regional lymph nodes (paraaortic and parailiaca 
lymph nodes). The presence of typical features of 
symptoms, signs, imaging and significant increase of 
CA 19-9 (typical tumor marker) could strengthen the 
suspicion of advanced stage pancreatic cancer (stage 
IV) according to the American Joint Committee on 
Cancer (AJCC). Based on that stadium, the prediction 
of this patient’s survival in 5 years was only 2%.
Tumor marker is one of the investigations performed 
for identifying or screening for cancer. Cancer antigen 
(CA) 19-9 is the only tumor marker recommended 
by the National Academy of Chemical Biochemistry 
(NACB), European Group on Tumors and American 
Gastroenterological Association (EGTM) to screen for 
pancreatic cancer. CA 19-9 is also used to assess the 
prognosis and monitor the response of the  treatment 
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that had been given. The sensitivity of CA 19-9 is 70-
90% and specificity is 90%. The combination of CA 
19-9 and the imaging diagnostic examination raise the 
suspicion of pancreatic cancer.2
Only 10% of patients with non-metastastic local 
disease are allowed for resection surgery. Outcome 
is better in patients with small tumors (< 3 cm), 
well-differentiated tumors and with no lymph node 
involvement. Approximately 30% of locally advanced 
patients can not be resected although having no 
metastasis. Approximately 60% of patients have 
metastases. Patients with poor performance status do 
not get benefit from chemotherapy.7 The definition 
of patient which can be resected or not is considered 
by the presence of involvement of the celiac artery, 
superior mesenteric artery, portal vein or inferior vena 
cava and the presence of distant metastases (including 
non-regional lymph node metastasis).10
The management of pancreatic cancer patients 
with distant metastases is placement of SEMS in 
the presence of jaundice. If the patients have good 
performance status, they can get various chemotherapy 
options. However, if the patients have bad performance 
status, they can get chemotherapy with gemcitabine or 
receive palliative therapy.10
Because there were an unresectable advance stage 
disease due to the involvement of distant lymph nodes 
and an obstructive biliary system, we performed ERCP 
and SEMS placement to the patient. The patient had 
symptomatic ECOG 3 score, where more than 50% 
of her activity was in bed, but not bed-bound (still 
limited to own limited requirement, 50% confined to 
bed or chair). Furthermore, patient was given palliative 
management and did not receive chemotherapy due to 
inadequate chemotherapy requirement (such as still 
had hyperbilirubinemia).
Appropriate ERCP indications are jaundice caused by 
biliary obstruction (appropriate therapeutic maneuvers 
performed during the procedure) and pancreatic duct 
disorders.11 In his review, Higuera et al conclude 
that treatment of pancreatic cancer at old age patient 
with score of ECOG > 2 is palliative therapy. Biliary 
obstruction was observed in more than 70% pancreatic 
cancer patients and most of them had perendoscopic 
stents placement and resolution is obtained in 90% of 
cases. Biliary bypass surgery was an advanced option 
in patients who were not effective with stent.12
To achieve a longer duration for patency of the 
stent, SEMS is preferred than plastic stents. Based 
on previous study, it is said that plastic stents had 
more complications and higher rate of hospitalization 
compared with metallic stent. Although SEMS is more 
expensive than plastic stents, the existing data indicates 
its superiority in the patency and outcome of patients 
(safer and more cost effective).4
More recent literatures had focused on comparing 
the different types of SEMS used in patients undergoing 
neoadjuvant therapy or in palliative cases. Major 
categories of SEMSs include uncovered (USEMSs) 
and covered (CSEMSs) groups. USEMSs have a 
mesh design that allows them to embed in the biliary 
duct wall but it also makes them susceptible to tissue 
ingrowth, which can lead to occlusion in as many as 
20% of patients. CSEMSs are designed to prevent 
tissue ingrowth, but because of this they are known to 
have increased rates of migration.4
To our patient, we performed stent placement using 
SEMS Boston ® Wallflex Uncovered 10 mm 8 cm, thus 
the possibility for migration from SEMS was less. As for 
reocclusion causing biliary reobstruction might happen 
in the future, the patient reqired to be re-observed.
Another focus in the management of malignant 
biliary obstruction is the placement of stents for 
palliative purposes in non-curable pancreatic cancers. 
The rationales for stent placement occurs in patients 
with neoadjuvant therapy are reducing jaundice and 
pruritus, normalizing bilirubin levels for palliative 
chemotherapy and preventing other complications such 
as cholangitis, recurrent hospitalization, and  overall 
quality of life improvement. However in patients 
with advanced disease and short life expectancy, 
using SEMS because long-term stent patency is not 
an objective in this case. Plastic stents will be more 
effective in cost in patients with distant metastases and 
short-life expectancy.4,13
A meta-analysis study showed that SEMS is only 
cost-effective if patient survival is > 4 months (studies 
show that patients with liver metastases have a median 
survival time of 2.7 months compared with 5.3 months 
in patients without liver metastases). Other study 
concluded that SEMS should be useful in patients 
with no distant metastases.4 According to Sperti et al, 
although the involvement of paraaortic lymph nodes 
was one form of distant metastases, but paraaortic 
lymph node metastases was only associated with 
short survival rates in univariate analysis. Sperti et al 
concluded that paraaortic lymph node metastases was 
not an independent prognostic factor.14
Patients obtained palliative SEMS insertion in 
accordance to NCCN guideline. Based on the AJCC 
criteria the patient had entered at stage IV disease 
due to metastases to the paraaortic and parailiaca 
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lymph nodes. In general, the prediction of survival in 
5 years of stage IV is 2%, but this might be different 
because paraaortic lymph nodes were not independent 
prognostic factors.
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Figure 1. Perendoscopic placement of SEMS in pancreatic head 
malignancy
Figure 2. Fluoroscopy of SEMS in pancreatic head malignancy 
CONCLUSION
Malignant biliary obstruction due to pancreatic 
cancer is associated with poor outcomes and low 
survival rate. Biliary decompression can improve 
the quality of life and mortality of patients. The role 
of stent placement in biliary decompression is more 
pronounced in locally advanced disease and patients 
with incurable for palliative purposes. Several studies 
had demonstrated the superiority of SEMS compared 
to plastic stents in long-term stent patency and 
improvement in patient outcomes.
